Tafasitamab

In this video, Jason Westin, MD, discusses the results of the Smart Stop trial, presented at ASH Annual Meeting and Exposition.

Treatment regimens for diffuse large B-cell lymphoma have seen many recent advancements, thanks in large part to the development of targeted agents.

Amyloidosis is a disease in which specific precursor proteins misfold into beta-pleated sheets. Misfolded proteins adhere to form oligomers resulting in insoluble amyloid fibrils that deposit into tissue.

The FDA granted priority review to tafasitamab in combination with lenalidomide for treatment of patients with relapsed or refractory diffuse large B-cell lymphoma, according to the agent’s manufacturer.